Mclean Hospital

mcleanhospital.org

Total trials

180

Active

35

Phase 3

7

Total enrollment

15,433

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
MitoQ1
D-cycloserine4
Cannabidiol4
Nociceptin Receptor Antagonist2
Dextromethophan1
Magnesium vitamin B61
D-serine1
Nicotinamide riboside2
Lorazepam2
high CBD/low THC sublingual solution1
Baclofen1
Memantine4
PET radiotracer1

Next readouts

  • 2026-05-15
  • 2026-06
  • 2026-10
  • 2026-10-28
  • 2026-12
  • 2026-12
  • 2026-12-26
  • 2027-01-31
  • 2027-03-31
  • 2027-06

Top conditions

  • Major Depressive Disorder23
  • Bipolar Disorder20
  • Depression14
  • Schizophrenia12
  • Bipolar Depression12
  • Nicotine Dependence12
  • Anxiety9
  • Schizoaffective Disorder9

Frequently asked questions about Mclean Hospital

How many clinical trials does Mclean Hospital have on ClinicalTrials.gov?
Mclean Hospital is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
How many of Mclean Hospital's trials are in Phase 3?
7 of Mclean Hospital's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Mclean Hospital focus on?
Mclean Hospital's most-studied conditions on ClinicalTrials.gov are Major Depressive Disorder, Bipolar Disorder, Depression, Schizophrenia, Bipolar Depression.
When are Mclean Hospital's next clinical trial readouts?
Mclean Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia”, expected around 2026-05-15.